Plain-English translation of NCT05104515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is the first time is being tested in humans. Researchers want to find out if this new cancer vaccine is safe and how well it works against advanced lung, ovarian, or prostate cancer. The study will start with small groups of patients receiving increasing doses to find the safest amount, then give that dose to more patients to confirm safety and see if it helps control their cancer.
Many patients with advanced lung, ovarian, and prostate cancer run out of standard treatment options or need a break from traditional therapies. This medication is designed to work differently—by helping the body's immune system recognize and fight cancer cells—offering a potential new approach for people whose cancers have progressed despite other treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive three injections of the medication under your skin, given two weeks apart. You will visit the hospital about 10 times over roughly 6 months for these injections and to have blood tests and scans to check for side effects and whether your cancer is responding. The study takes place at approximately five sites across the UK, and your care team will monitor you closely to make sure the treatment is working and safe for you.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United Kingdom